Nanjing (China) and Barcelona (Spain), a global biopharmaceutical company focused on skin health, and Simcere Pharmaceutical Group（2096.HK), an innovation and R&D-driven pharmaceutical company; today announced that they have entered into an exclusive licensing agreement for Simcere’s IL-2 mutant fusion protein (IL-2 mu-Fc) autoimmune drug candidate, SIM0278. Under the agreement, Almirall will be granted an exclusive right to develop and commercialise SIM0278 for all indications outside of the Greater China region (Mainland China, Hong Kong, Macau and Taiwan). Simcere will retain all rights to develop and commercialise SIM0278 within Greater China. Within the terms of the agreement, Simcere will receive a $15 million upfront payment, and up
The post Almirall and Simcere enter into a licensing agreement for IL-2-mu-Fc appeared first on Pharma Mirror Magazine.
